Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. D. Boral Capital’s price target would suggest a potential upside of 148.55% from the stock’s previous close.

Several other research firms have also weighed in on COYA. BTIG Research reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 30th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, October 8th. Lake Street Capital restated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a report on Wednesday, November 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, September 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.80.

Coya Therapeutics Stock Performance

NASDAQ COYA traded up $0.03 on Wednesday, reaching $6.04. The company’s stock had a trading volume of 121,481 shares, compared to its average volume of 100,529. The firm’s 50 day moving average is $6.11 and its two-hundred day moving average is $6.05. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $8.29. The stock has a market cap of $101.03 million, a PE ratio of -4.87 and a beta of 0.20.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COYA. CM Management LLC boosted its position in shares of Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after acquiring an additional 40,000 shares during the period. Dauntless Investment Group LLC acquired a new stake in Coya Therapeutics in the 1st quarter worth $1,083,000. Charles Schwab Investment Management Inc. acquired a new stake in Coya Therapeutics in the 1st quarter worth $65,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Coya Therapeutics during the 2nd quarter worth about $119,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics during the third quarter valued at about $28,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.